Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients.
about
Human cytomegalovirus resistance to antiviral drugsHow I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipientsAntiviral drug resistance in human cytomegalovirusAntiviral drug resistance: mechanisms and clinical implicationsDetection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridizationIn vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosineTreatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, interferon, and bropirimineNonnucleoside pyrrolopyrimidines with a unique mechanism of action against human cytomegalovirusPotent antiviral activity of an antisense oligonucleotide complementary to the intron-exon boundary of human cytomegalovirus genes UL36 and UL37A novel peptide aldehyde with activity against human cytomegalovirus in two different in vivo modelsAnti-herpesvirus activities and cytotoxicities of 2-thiopyrimidine nucleoside analogues in vitroAntiviral drug resistance of human cytomegalovirus.Therapeutic use of ganciclovir for invasive cytomegalovirus infection in cadaveric renal allograft recipientsClinically resistant cytomegalovirus retinitis.Medical and virological aspects of ocular human immunodeficiency virus infection for the ophthalmologist.Resistance of human cytomegalovirus to antiviral drugs.Nucleotide analogs related to acyclovir and ganciclovir are effective against murine cytomegalovirus infections in BALB/c and severe combined immunodeficient miceClinical uses of cidofovir.Disseminated cytomegalovirus infection.A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates.Non-nucleosidic inhibition of Herpes simplex virus DNA polymerase: mechanistic insights into the anti-herpetic mode of action of herbal drug withaferin AMutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma.Prevention and treatment of cytomegalovirus infection in organ transplant recipients.Identification of cell surface receptors for the 86-kilodalton glycoprotein of human cytomegalovirus.Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation.Complete sequence and genomic analysis of rhesus cytomegalovirusNovel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovirEvaluation of retinal toxicity and efficacy of the anticytomegalovirus compound 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine.Potent anti-murine cytomegalovirus activity and reduced nephrotoxicity of ganciclovir cyclic phosphonate.Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymeraseTreatment of herpesvirus infections in HIV-infected individuals.Resistance of herpesviruses to antiviral drugsA point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives.Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients.The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines.RNA interference-mediated targeting of human cytomegalovirus immediate-early or early gene products inhibits viral replication with differential effects on cellular functions.Antiviral therapy: current concepts and practicesEpigenetically repressing human cytomegalovirus lytic infection and reactivation from latency in THP-1 model by targeting H3K9 and H3K27 histone demethylases.Leflunomide: a possible alternative for gangciclovir sensitive and resistant cytomegalovirus infections.Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients.
P2860
Q24556634-F2B261D4-C2D6-4F1E-B27F-5BF2E1BF4528Q28069489-7910ADB8-FF17-45D3-9B98-2B6898DAA73BQ28203967-156A93A2-351A-4C5A-8515-77D024F62EAEQ28282376-49AA6921-C21E-4D57-8268-1599CB5E8B08Q28323773-EF1143D2-C4E2-4CBD-B0A1-8518EC450886Q28324338-86B14C0F-2594-42DF-BD67-C3D4798E4CB6Q28326886-ABD2F784-E768-43F7-BD9A-0D2FA4592C34Q28343467-463F45E3-3272-47F1-B67F-74F746512AF0Q28367898-BF69DF17-972D-4AB0-AF0F-7D1B8B00922FQ28371858-089F7E48-E119-4826-BA7D-69F698566175Q28372628-828F824B-E593-4BC5-B555-70B6858BFF7FQ30430427-42D9D44A-68B8-4425-B681-C5D2ADAFB300Q33351296-AFA8725F-5BD6-47B5-A0E4-2B0E4C9DA349Q33569554-2E9EFF43-46BC-41C7-839E-DC44003CB55BQ33569593-E5A9FD6D-F112-4B87-BB5E-6BCF3EE7334AQ33588911-DB28D584-3675-4AD7-B8EB-01D11646596CQ33759331-9A5F7BE3-542D-4256-A23C-FEE69ABF89BEQ33867391-6B80048C-D43D-47FE-8674-55076CE9BB9BQ33933519-48F0D528-F243-4755-9538-6999F9C94311Q33978966-96719956-E07B-40FD-BD5C-D6909CB1DE23Q34175625-1B9B37D0-B4CC-4E45-A4F5-CB2D2DCCECEDQ34195000-BC762972-05D7-48D1-B8AA-B7F04B1FF3F9Q34294851-A96942AE-B279-414D-ABB9-645D150B4EB2Q34326797-B13556CE-FE96-4789-8026-35735344E862Q34549241-232D9B86-340B-4EF6-8D17-E5C5925048A0Q35020562-2FAC893D-9452-4D8F-96EB-A06D34C2EA81Q35114921-D3383B6A-CA8F-400C-B917-821059A9425BQ35116034-BF952DDD-8093-48E6-A8AE-E15525A7EB4AQ35126399-C1CC77A4-DC97-4764-8529-646B32333B1DQ35139402-75FC90C2-2BFF-4833-A169-D8D126473410Q35231928-91B3E86E-257D-4BC4-B381-3722478DBEBAQ35447500-B84BF985-72B2-4673-B22A-715FAFC7ED3EQ35807437-358FBE75-CC24-452E-B514-811524487C49Q35816311-481F94A9-96D6-463C-856C-6EA55911346AQ35874959-6386E707-D1EA-4674-A1F6-D0672D744166Q35943427-4BC951D4-BE22-47D5-A227-3237A4D89520Q36070394-CBFC4787-89A3-4CB4-9F07-23CC91D2E991Q36346073-9528815D-CACB-41FC-863E-B6509E12C03FQ36470482-B73F8D5F-A020-41AE-83D2-33AF4865EB2AQ36753818-FBE09310-617E-40D7-8615-F5693C3F0501
P2860
Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Progressive disease due to gan ...... in immunocompromised patients.
@en
Progressive disease due to gan ...... in immunocompromised patients.
@nl
type
label
Progressive disease due to gan ...... in immunocompromised patients.
@en
Progressive disease due to gan ...... in immunocompromised patients.
@nl
prefLabel
Progressive disease due to gan ...... in immunocompromised patients.
@en
Progressive disease due to gan ...... in immunocompromised patients.
@nl
P2093
P1476
Progressive disease due to gan ...... in immunocompromised patients.
@en
P2093
P304
P356
10.1056/NEJM198902023200505
P407
P577
1989-02-01T00:00:00Z